DOCSLIB.ORG

Institute of Bioinorganic and Radiopharmaceutical C H E M I S T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Institute of Bioinorganic and Radiopharmaceutical C H E M I S T INSTITUTE OF BIOINORGANIC AND RADIOPHARMACEUTICAL CHEMISTR~ Annual Report 1996 Cover picture: Space-filling model of a first serotonin receptor-binding technetium-99m molecule. Forschungszentrum Rossendorf e. V. Postfach 51 01 19; D-01314 Dresden Bundesrepublik Deutschland Telefon (03 51) 260 31 70 Telefax (03 51) 260 32 32 E-Mail johannsenafz-rossendorf.de FZR - I65 February 1997 AnnuaI Report 1996 Institute of Bioinorganic and Radiopharmaceutical Chemistry Editor: B. Johannsen Editorial staff: S. Seifert FOREWORD Research at the Institute of Bioinorganic and Radiopharmaceutical Chemistry of the Research Center Rossendorf Inc. is focused on radiotracers as molecular probes for diagnosis of disease. Denved from an awareness of the very important role modern nuclear medicine is playing, as expressed explicitly in the synonym in vivo biochemi~stry,this research effort has two main components: positron emission tomography (PET) technetium chemistry and radiopharmacology. To make positron emission tom~ographyavailable also in the eastern part of Germany, a PET center was established at Rossendorf. As envisaged in a contract signed in February 1995 between the Research Center Rossendorf and the Dresden University of Technology, the lnstitute is closely linked to the University Hospital in this PET center. A joint team of staff mernberc from both the lnstitute and the Department of Nuclear Medicine with the University Hospital has been working at the Rossendorf PET Center. To contribute to further exploitiation of technetium-99m with its ideal nuclear properties for single photon emission tomography (SPECT), great commitment to interdisciplinary research into technetium tracers is required. The Institute's projects therefore address new approaches to tracer design. The research activities of our Institute have been performed in three administrative1 classified groups. A PET tracer group is engaged in the chemistry and radiopharmacy of 'G and "F compounds and in the setup of the PET center, which is jointly tun by the lnstitute and the Clinic and Polyclinic of Nuclear Medicine at the University Hospital. A SPECT tracer group deals with the design, synthesis and chernical characterization of metal coordination compounds, primarily rhenium and technetium cornplexes. A biochemical group is working on SPECT and PET-relevant biochemical and biological projects. This includes the characterization and assessment of new cornpounds developed in the two synthetically oriented groups. The annual report presented here Covers the research activities of the Institute of Bioinorganic and RadiopharmaceuticalChemistry in 1996. The achievements attained so far have only been possible because of the dedication and commitment of the permanent and temporary staff, the Ph.D. students and collaborators inside and outside the Rossendorf Research Center Inc. Iwould like to extend my thanks to all of them. Bemd Johannsen CONTENTS I. RESEARCH REPORTS 1. Serotonin Receptor-Binding Technetium and Rhenium Complexes 9. Synthesis and Characterization of Ligands Derived from Partial StructureS of Ketanserin, Cisapride and MDL 72832 M. Scheunemann, H.-J. Pietzsch, H. Spies, P. Brust, B. Johannsen 2. Serotonin Receptor-Binding Technetium and Rhenium Complexe~ 10. Synthesis and Characterization of Rhenium and Technetium Complexes Derived from Partial Structures of Ketanserin, Cisapride and MDL 72832 M. Scheunemann, H.-J. Pietzsch, H. Spies, P. Brust, B. Johannsen 3. Serotonin Receptor-BindingTechnetium and Rhenium Complexes II. Affinity and Selectivity of OxorheniumOl) Complexes Derived from Ketanserin, Cisapride and MDL 72832 H.-J. Pietzsch, M. Scheunemann, P. Brust, J. Wober, H. Spies, B. Johannsen 4. Serotonin Receptor-Binding Technetium and Rhenium Complexes 12. Structural Modification of Receptor-BindingTechnetium-99m Complexes in oder to lmprove Brain Uptake B. Johannsen, R. Berger, P. Brust, H.-J. Pietzsch, M. Scheunemann, S. Seifert, H. Spies, R. Syhre 5. Serotonin Receptor-Binding Technetium and Rhenium Complexes 13. No Carrier Added Preparations of "3+lu""'TC Complexes S. Seifert, H.-J. Pietzsch, M. Scheunemann, H. Spies, R. Syhre, B. Johannsen 6. Serotonin Receptor-Binding Technetium and Rhenium Complexes 23 14. Distribution and Brain Uptake in Rats of Serotonin Receptor-Binding Oxotechnetium01) Complexes at the c.a. (99m9 Tc) and the n.c.a. (99m~c)Level R. Syhre, H.-J. Pietzsch, M. Scheunemann, S. Seifert, H. Spies. B. Johannsen 7, Serotonin Receptor-Binding Technetium and Rhenium Complexes 15. Synthesis and Characterization of Oxorhenium01) Complexes with N-Functionalized Tridentate SWS Ligands H.-J. Pietzsch, M. Scheunemann, R. Berger, H. Spies, B. Johannsen 8. Synthesis of Neutral Amine Groiup Bearing "3+IuMixed-Ligand Complexes of 35 Oxorhenium01) M. Friebe, M.Papadopoulos, S.Chiotellis, H. Spies, R. Berger, B. Johannsen 9. Preparation of Amine Group Bearing "3+IuMixed-Ligand Oxotechnetium01) 40 complexes at the camer added level M. Friebe, M.Papadopoulos, E.Chiotellis, H. Spies, R. Berger, B. Johannsen 10. Lipophilicity and lonization Properties of Some Amine-Bearing Technetium and 43 Rhenium "3+lUMixed-Ligand Chelates with Same Ligand Structure R. Berger, M. Friebe, H.-J. Pietzsch, M. Scheunemann, B. Noll, T. Fietz, H. Spies, B. Johannsen 11. Retropane - a New Rhenium Complex as a Potential Ligand of the Dopamine Transporter A. Hoepping, H. Spies, B. Johannsen 12. Preparation and Structure of Neutral 0x0-Re01)-Complexes with L-Cysteine Methyl Ester and D-Peniciliamine Methyl Ester S. Kirsch, B. Noll, H. Spies, B. Johannsen, P. Leibnitz, D. Scheller 13. Formation of Mixed-Ligand Ester Complexes of Rhenium and Technetium with S/S/S-N or S-S/S-N Coordination S. Seifert, H. Spies 14. A Novel Amide Thioether Dithiolate Ligand Derived from Cysteine B. Noll, S. C. Hilger, P. Leibnitz, H. Spies, L. Dinkelborg, B. Johannsen 15. Novel OxorheniumO/) Complexes with Cysteinylglycine and Glycylglycylcysteine: Preparation and Characterization in Solution S. Kirsch, R. Jankowsky, B. Noll, H. Spies, B. Johannsen, D. Scheller 16. Synthesis and Characterization of Technetium and Rhenium Oligoglycine Complexes and Technetium Tartrate R. Jankowsky, B. Nol, H. Spies, B. Johannsen 17. XAS Investigations on Tc and Re Complexes of Oligoglycine Ligands and Tc Tartrate R. Jankowsky, B. Noll, H. Spies, B. Johannsen 18. X-Ray Absorption Spectroscopy: A Valuable Tool for Structural Analysis of Tc and Re Complexes R. Jankowsky, B. Noll, H. Spies, T. Reich, H. Nitsche 19. Technetium and Rhenium Complexes with Thioether Ligands. 8. X-Ray Structures of Mononuclear Oxorhenium01) Complexes with Bidentate Thioether and Dithiaalcohol Ligands M. Reisgys, H.-J. Pietzsch, H. Spies, P. Leibnitz 20. Rhenium and Technetium Carbonyl Complexes for the Labelling of Bioactive Molecules. 2. Tricarbonylrhenium(1) Complexes with Mono-, Bi- and Tridentate Thioether Ligands H.-J. Pietzsch, M. Reisgys, H. Spies, R. Albedo, U. Abram 21. Technetium and Rhenium Labelled Steroids. I.First Synthesis of "3+lVMixed-Ligand Oxorhenium01) Complexes Bearing a Pendent Estradiol Moiety F. Wüst, H. Spies, D. Scheller, S. Machill 22. Technetium and Rhenium Labelled Steroids. 2. Oxorhenium01) Complexes of 1-Mercapto-4-Methylestra-I ,3,5(10)-trien-I 7-one F. Wüst, H. Spies, R. Becked, S. Möller 23. Structure and Reactivity of a "3+IuMixed-Ligand Rhenium Complex Containing Thiobenzoate as a Monodentate Ligand [ReO(SSS)(SC(O)Ph)J B, Noll, P. Leibnitz, St. Noll, R. M. Mahfouz, H. Spies 24. Nicotinamide Substituted Rhenium0 Mixed-Ligand Complexes T. Kniess, H. Spies 25. Dihydropyiidine Substituted TechnetiurnOl) Mixed-Ligand Complexes T. Kniess, H. Spies 26. Note to Fast Hydrolysis of the Methyl Ester of MAGz during Complexation with TcJRe(V) Gluconate St. Noli, B. Noll, H. Spies 27. Synthesis of la6~eGluconate by Stannous Chloride Reduction of lE6~e0i B. Noll, T. Kniess, H. Spies 28. Determination of Partition Coefficients for Coordination Compounds by Using the HPLC Column Nucleogel RP Cla 80-10 R. Berger, T. Fietz, M. Glaser, H. Spies 29. lnvestigations of Serotonin Receptor Subtypes on the Blood-Brain Barrier J. Wober, S. Matys, P. Brust 30. Comparison of a Microplate Assay with Conventional Binding Assay for the Screening of Potential Receptor Ligands J. Wober, P. Brust 31. Functional Expression of P-Glycoprotein in an lmmortalized Rat Brain Endothelial Cell Line (RBE4) in vitro R. Bergmann, S. Matys, P. Brust 32. Different Response of Cerebral and Non Cerebral Endothelial Cells to Cytotoxic Hypoxia. B. Ahlemeyer, P. Brust, B. Johannsen 33. Studies on an HPLC Method to Assay the Concentrations of Amines in Brain Micro- dialysis Perfusates Based on Naphthalene-2,3-Dicarbaldehyde Derivatization and Fluorescence Detection G. Vorwieger, R. Bergmann, P. Brust, B. Johannsen 34. High-Affinity Binding of [3~]~aroxetineto Caudate Nucleus and Microvessels from Porcine Brain P. Brust, R. Bergmann, B. Johannsen 35. Measurement of the Cerebral Uptake and Metabolism of L-6-["~] Fluoro-3,4-Dihydroxy-Phenylalanine in Newborn Piglets P. Brust, R. Bauer, R. Bergmann, B. Walter, J. Steinbach, F. Füchtner, E. Will, H. Linemann, M. Obert, U. Zwiener, B. Johannsen 36. High Yield Preparation of 6-['8~]~luoro-~~~~ F. Füchtner, K. Günther, J. Steinbach, R. Lücke, R. Scholz, R. Hüller 37. Modified Access to the Thioester Precursor of ["C](+)-MCN-5652-z J. Zessin, P. Brust, J. Steinbach 38. Substances Labelled in Metabolically Stable Positions: The Conversion of Pyrylium Salts with Nitro-["clmethane - a New Method for the Synthesis of n.c.a.
Load more

Recommended publications
  • Bromobenzene D5
    Safety data sheet according to Regulation (EC) No. 1907/2006 (REACH), amended by 2015/830/EU Bromobenzene D5 99,5 Atom%D article number: HN93 date of compilation: 2020-09-02 Version: 1.0 en SECTION 1: Identification of the substance/mixture and of the company/ undertaking 1.1 Product identifier Identification of the substance Bromobenzene D5 99,5 Atom%D Article number HN93 Registration number (REACH) It is not required to list the identified uses be- cause the substance is not subject to registration according to REACH (< 1 t/a) EC number 224-013-8 CAS number 4165-57-5 1.2 Relevant identified uses of the substance or mixture and uses advised against Identified uses: laboratory chemical laboratory and analytical use 1.3 Details of the supplier of the safety data sheet Carl Roth GmbH + Co KG Schoemperlenstr. 3-5 D-76185 Karlsruhe Germany Telephone: +49 (0) 721 - 56 06 0 Telefax: +49 (0) 721 - 56 06 149 e-mail: [email protected] Website: www.carlroth.de Competent person responsible for the safety data : Department Health, Safety and Environment sheet: e-mail (competent person): [email protected] 1.4 Emergency telephone number Name Street Postal code/ Telephone Website city National Poisons Inform- Dudley Rd B187QH Birm- 844 892 0111 ation Service ingham City Hospital Emergency information service +49/(0)89 19240 SECTION 2: Hazards identification 2.1 Classification of the substance or mixture Classification according to Regulation (EC) No 1272/2008 (CLP) Classification acc. to GHS Section Hazard class Hazard class and cat- Hazard egory state- ment 2.6 flammable liquid (Flam.
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Chem 353: Grignard
    GRIG.1 ORGANIC SYNTHESIS: BENZOIC ACID VIA A GRIGNARD REACTION TECHNIQUES REQUIRED : Reflux with addition apparatus, rotary evaporation OTHER DOCUMENTS Experimental procedure, product spectra INTRODUCTION In this experiment you will synthesise benzoic acid using bromobenzene to prepare a Grignard reagent, which is then reacted with carbon dioxide, worked-up and purified to give the acid. This sequence serves to illustrate some important concepts of practical synthetic organic chemistry : preparing and working with air and moisture sensitive reagents, the "work-up", extractions, apparatus set-up, etc. The synthesis utilises one of the most important type of reagents discussed in introductory organic chemistry, organometallic reagents. In this reaction, the Grignard reagent (an organomagnesium compound), phenylmagnesium bromide is prepared by reaction of bromobenzene with magnesium metal in diethyl ether (the solvent). The Grignard reagent will then be converted to benzoic acid via the reaction of the Grignard reagent with excess dry ice (solid CO2) followed by a "work-up" using dilute aqueous acid : The aryl (or alkyl) group of the Grignard reagent behaves as if it has the characteristics of a carbanion so it is a source of nucleophilic carbon. It is reasonable to represent the structure of the - + Grignard reagent as a partly ionic compound, R ....MgX. This partially-bonded carbanion is a very strong base and will react with acids (HA) to give an alkane: RH + MgAX RMgX + HA Any compound with suitably acidic hydrogens will readily donate a proton to destroy the reagent. Water, alcohols, terminal acetylenes, phenols and carboxylic acids are just some of the functional groups that are sufficiently acidic to bring about this reaction which is usually an unwanted side reaction that destroys the Grignard reagent.
    [Show full text]
  • TOXICOLOGICAL REVIEW of BROMOBENZENE (CAS No
    EPA/635/R-07/002F www.epa.gov/iris TOXICOLOGICAL REVIEW OF BROMOBENZENE (CAS No. 108-86-1) In Support of Summary Information on the Integrated Risk Information System (IRIS) September 2009 U.S. Environmental Protection Agency Washington, DC DISCLAIMER This document has been reviewed in accordance with U.S. Environmental Protection Agency policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. ii CONTENTS−TOXICOLOGICAL REVIEW OF BROMOBENZENE (CAS No. 108-86-1) LIST OF TABLES......................................................................................................................... vi LIST OF FIGURES ....................................................................................................................... ix LIST OF ABBREVIATIONS AND ACRONYMS ....................................................................... x FOREWORD ................................................................................................................................. xi AUTHORS, CONTRIBUTORS, AND REVIEWERS ................................................................ xii 1. INTRODUCTION ..................................................................................................................... 1 2. CHEMICAL AND PHYSICAL INFORMATION RELEVANT TO ASSESSMENTS .......... 3 3. TOXICOKINETICS .................................................................................................................. 6 3.1. ABSORPTION ................................................................................................................
    [Show full text]
  • The Ozonolysis of Phenyl Grignard Reagent
    University of Montana ScholarWorks at University of Montana Graduate Student Theses, Dissertations, & Professional Papers Graduate School 1971 The ozonolysis of phenyl Grignard reagent Gale Manning Sherrodd The University of Montana Follow this and additional works at: https://scholarworks.umt.edu/etd Let us know how access to this document benefits ou.y Recommended Citation Sherrodd, Gale Manning, "The ozonolysis of phenyl Grignard reagent" (1971). Graduate Student Theses, Dissertations, & Professional Papers. 8297. https://scholarworks.umt.edu/etd/8297 This Thesis is brought to you for free and open access by the Graduate School at ScholarWorks at University of Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact [email protected]. THE OZONOLYSIS OF PHENYL GRIGNARD REAGENT By Gale M. Sherrodd B.S., Rocky Mountain College, I969 Presented in partial fulfillment of the requirements for the degree of Master of Arts for Teachers UNIVERSITY OF MONTANA 1971 Approved by: Chairman, Board of Examiners De^ , Graduate *School / n ? / Date Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. UMI Number: EP39098 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. UMT DiMMtstion PuWiahing UMI EP39098 Published by ProQuest LLC (2013). Copyright in the Dissertation held by the Author.
    [Show full text]
  • TOXICOLOGICAL REVIEW of BROMOBENZENE (CAS No
    DRAFT - DO NOT CITE OR QUOTE EPA/635/R-07/002 www.epa.gov/iris TOXICOLOGICAL REVIEW OF BROMOBENZENE (CAS No. 108-86-1) In Support of Summary Information on the Integrated Risk Information System (IRIS) June 2007 NOTICE This document is an interagency review draft. It has not been formally released by the U.S. Environmental Protection Agency and should not at this stage be construed to represent Agency position on this chemical. It is being circulated for review of its technical accuracy and science policy implications. U.S. Environmental Protection Agency Washington, DC DISCLAIMER This document is a preliminary draft for review purposes only and does not constitute U.S. Environmental Protection Agency policy. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. 6/7/07 ii DRAFT – DO NOT CITE OR QUOTE CONTENTSCTOXICOLOGICAL REVIEW OF BROMOBENZENE (CAS No. 108-86-1) LIST OF FIGURES ....................................................................................................................... vi LIST OF TABLES........................................................................................................................ vii LIST OF ABBREVIATIONS AND ACRONYMS ........................................................................x FOREWORD ................................................................................................................................. xi AUTHORS, CONTRIBUTORS, AND REVIEWERS ................................................................ xii
    [Show full text]
  • Nandrolone Technical Document July 04 V1.0
    WADA Technical Document – TD2004NA Document Number: TD2004NA Version Number: 1.0 Written by: WADA Laboratory Committee Approved by: WADA Executive Committee Date: 28 May, 2004 Effective Date: 13 August, 2004 REPORTING NORANDROSTERONE FINDINGS 1. Introduction: This document has been established to harmonize analysis and reporting of norandrosterone Adverse Analytical Findings by Laboratories. The administration of 19-norsteroids such as 19-nortestosterone (nandrolone), 19-norandrostene-3,17- dione and 19-norandrostene-3,17-diol (delta-4 and -5 isomers) has been shown to lead mainly to the excretion of 19-norandrosterone (NA), 19-noretiocholanolone (NE) and 19-norepiandrosterone (NEA). The latter is found exclusively as its sulfoconjugate while the others are usually excreted as their glucuronide derivative. The sulfate derivatives, generally persistent, may be prevalent at the end of the excretion period. After the i.m. administration of the long-lasting preparations of nandrolone, the metabolites may be detected for months, but metabolites formed after the oral ingestion are excreted massively in the first hours and remain detectable for only a few days. The excretion of 19-norandrosterone generally predominates that of the 5b-isomer but inversed proportions have been reported in some individuals after oral administration either at the end of the excretion period or when ? 5-isomers of related norsteroids were taken (1). Norandrosterone is excreted during pregnancy and2010 as a minor metabolite of norethisterone (2). Special procedures such as more sensitive instrumentation, larger volumes of urine and more extensive sample clean-up were needed to detect, identify and quantify endogenous 19-norandrosterone (with limits of detection needing to be ten times lower than routine testing i.e.
    [Show full text]
  • Steroids – Basic Science
    STEROIDS – BASIC SCIENCE Edited by Hassan Abduljabbar Steroids – Basic Science Edited by Hassan Abduljabbar Published by InTech Janeza Trdine 9, 51000 Rijeka, Croatia Copyright © 2011 InTech All chapters are Open Access distributed under the Creative Commons Attribution 3.0 license, which allows users to download, copy and build upon published articles even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. After this work has been published by InTech, authors have the right to republish it, in whole or part, in any publication of which they are the author, and to make other personal use of the work. Any republication, referencing or personal use of the work must explicitly identify the original source. As for readers, this license allows users to download, copy and build upon published chapters even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. Notice Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained in the book. Publishing Process Manager Bojan Rafaj Technical Editor Teodora Smiljanic Cover Designer InTech Design Team Image Copyright loriklaszlo, 2011. DepositPhotos First published December, 2011 Printed in Croatia A free online edition of this book is available at www.intechopen.com Additional hard copies can be obtained from [email protected] Steroids – Basic Science, Edited by Hassan Abduljabbar p.
    [Show full text]
  • Synthesis of Organobromines As a Tool for Their Characterisation and Environmental Occurrence Assessment
    Synthesis of organobromines as a tool for their characterisation and environmental occurrence assessment Andreas Rydén Department of Materials and Environmental Chemistry Stockholm University Stockholm 2013 i Doctoral Thesis 2013 Department of Materials and Environmental Chemistry Stockholm University SE-106 91 Stockholm Sweden Abstract Polybrominated diphenyl ethers (PBDEs) have been intensively used as flame retardants (FRs) and have become ubiquitous environmental pollutants. PBDEs form hydroxylated PBDEs (OH-PBDEs) as metabolites. Further, some OH-PBDEs and methoxy-PBDEs (MeO-PBDEs) are natural products. These are all compounds of environmental and health concern and it is therefore important to confirm their identity and to assess their environmental levels and toxicities. Hence, it is vital to obtain authentic reference standards of individual PBDEs and OH/MeO-PBDEs. The thesis main aim was to develop synthesis methods of congener specific PBDEs, OH- and MeO-PBDEs. The second aim was to identify and quantify PBDEs, OH- and MeO-PBDEs in environmental samples. The third was to propose an abbreviation system for FRs. O-Arylation of brominated phenols, using either symmetrical or unsymmetrical brominated diphenyliodonium salts, was selected for synthesis of PBDEs and OH- /MeO-PBDEs. A total of 16 MeO-PBDEs, 11 OH-PBDEs, 1 diMeO-PBDE and 1 EtO-MeO-PBDE were synthesised. Three novel unsymmetrical diaryliodonium triflates were synthesised and used in synthesis. Optimisations were made to construct a reliable general method for congener specific PBDE synthesis, which was used in the synthesis of 8 representative PBDE congeners. The products were generally characterised by electron ionisation mass spectrometry (EIMS) and nuclear magnetic resonance (NMR) spectroscopy.
    [Show full text]
  • LABORATORY 9 the Grignard Reaction: a Microscale Preparation
    Organic Chemistry: Techniques and Transformations LABORATORY 9 The Grignard Reaction: A Microscale Preparation of Benzoic Acid Introduction Your laboratory skills have grown considerably since the first of the semester, and you are ready for the challenge of a famous reaction--one marked by unusual materials and striking chemical and physical changes. Try, especially, to understand exactly which chemical structure and equation corresponds to each stage of this dramatic synthesis. Your work in this laboratory is a departure from your previous experience. You will work on a micro scale. Microscale apparatus is used throughout the second semester organic laboratories (CHEM 2130). Working on a microscale greatly reduces both the quantities of material and the reaction time. The regular scale reaction requires nearly two full periods. The microscale work can be done in one period. Further, the reduced scale minimizes the hazard of working with ether, a very flammable solvent with a low flash point. You must eliminate flames and sparks when working with ether. To run a successful Grignard reaction, it is essential that moisture (including water vapor from the air) be excluded from the reaction apparatus. Septa (rubber caps) on the reagent bottles and on the reaction tubes effectively exclude moisture, so that a calcium sulfate drying tube is unnecessary. A syringe, with a needle, is used to remove reagents from septum protected storage bottles and to add the reagent to a reaction tube. Thus, use of a syringe and septum eliminates the need for an addition funnel and a costly three-necked round-bottomed flask. There is less set-up time, less clean-up time and less breakage of expensive glassware.
    [Show full text]
  • Inhibition of Estrone Sulfate-Induced Uterine Growth by Potent Nonestrogenic Steroidal Inhibitors of Steroid Sulfatase1
    [CANCER RESEARCH 63, 6442–6446, October 1, 2003] Inhibition of Estrone Sulfate-induced Uterine Growth by Potent Nonestrogenic Steroidal Inhibitors of Steroid Sulfatase1 Liviu C. Ciobanu, Van Luu-The, Ce´line Martel, Fernand Labrie, and Donald Poirier2 Medicinal Chemistry Division, Oncology and Molecular Endocrinology Research Center, Centre Hospitalier Universitaire de Que´bec-Pavillon CHUL, and Universite´ Laval, Que´bec, G1V 4G2, Canada ABSTRACT thetic pathway accounts for the transformation of DHEAS into the estrogenic C19 steroid 5-diol. Thus, inhibition of steroid sulfatase, the The present study describes the biological in vitro and in vivo evaluation enzyme responsible for the conversion of DHEAS to dehydroepi- of 2-methoxy derivatives of estrogenic inhibitors of steroid sulfatase, androsterone and E StoE , may allow reduction of estrogen levels in namely 3-sulfamoyloxy-17␣-p-tert-butylbenzyl(or benzyl)-1,3,5 (10)- 1 1 estratrien-17␤-ols. The addition of the 2-methoxy group conserves the tumors and could represent a promising approach for the treatment of estrogen-sensitive breast cancer. potent inhibitory effect on steroid sulfatase activity (IC50s of 0.024 and 0.040 nM) while removing the estrogenic action. Using an ovariectomized Some of the most efficient steroid sulfatase inhibitors developed were mouse model, we show that the first generation of steroid sulfatase inhib- sulfamate derivatives (10–12). The first reported inhibitor in this series, itors tested, 3-sulfamoyloxy-17␣-p-tert-butylbenzyl(or benzyl)estra-1,3,5 estrone sulfamate (EMATE; Ref. 25, 26) is a very potent irreversible (10)-trien-17␤-ols and estrone-3-O-sulfamate, are estrogenic compounds inhibitor, but it is also an estrogenic compound (27), thus having less than stimulating estrogen-sensitive uterine growth.
    [Show full text]
  • Synthesis of Novel Azetidines
    University of New Orleans ScholarWorks@UNO University of New Orleans Theses and Dissertations Dissertations and Theses Fall 12-20-2013 Synthesis of Novel Azetidines Amber Thaxton UNO, [email protected] Follow this and additional works at: https://scholarworks.uno.edu/td Part of the Medicinal and Pharmaceutical Chemistry Commons, and the Organic Chemistry Commons Recommended Citation Thaxton, Amber, "Synthesis of Novel Azetidines" (2013). University of New Orleans Theses and Dissertations. 1764. https://scholarworks.uno.edu/td/1764 This Dissertation is protected by copyright and/or related rights. It has been brought to you by ScholarWorks@UNO with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in University of New Orleans Theses and Dissertations by an authorized administrator of ScholarWorks@UNO. For more information, please contact [email protected]. Synthesis of Novel Azetidines A Dissertation Submitted to the Graduate Faculty of the University of New Orleans in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Chemistry by Amber Nichole Thaxton B.S. Clemson University, 2004 M.S. University of New Orleans, 2013 December 2013 For my family: To my mom, Bee Thaxton, for everything she has done for me. I am extremely thankful for her constant support and reassurance.
    [Show full text]